Retatrutide Phase 3 Data Shows 29% Weight Loss, Rivaling Surgery
Eli Lilly's retatrutide triple agonist achieves 28.7% weight loss in TRIUMPH-4 trial, matching bariatric surgery outcomes and reshaping obesity treatment.
Eli Lilly's retatrutide triple agonist achieves 28.7% weight loss in TRIUMPH-4 trial, matching bariatric surgery outcomes and reshaping obesity treatment.